Literature DB >> 30133953

The relationship between pathologic lesions of active and chronic antibody-mediated rejection in renal allografts.

Mark Haas1.   

Abstract

The Banff classification of renal allograft pathology defines specific morphologic lesions that are used in the diagnosis of active (glomerulitis, peritubular capillaritis, endarteritis) and chronic (transplant glomerulopathy, peritubular capillary basement membrane multilayering, transplant arteriopathy) antibody-mediated rejection (ABMR). However, none of these individual lesions are specific for ABMR, and for this reason Banff requires 1 or more additional findings, including C4d deposition in peritubular capillaries, presence of circulating donor-specific antibodies (DSAs), and/or expression in the tissue of transcripts strongly associated with ABMR, for a definitive diagnosis of ABMR to be made. In addition, while animal studies examining serial biopsies have established the progression of morphologic lesions of active to chronic ABMR as well as intermediate forms (chronic active ABMR) exhibiting features of both, clear documentation that lesions of chronic ABMR require the earlier presence of corresponding active and intermediate lesions is less well established in human renal allografts. This review examines temporal relationships between key morphologic lesions of active and chronic ABMR in biopsies of human grafts, likely intermediate forms, and findings for and possibly against direct and potentially interruptible progression from active to chronic lesions.
© 2018 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  classification systems: Banff classification; kidney transplantation/nephrology; pathology/histopathology; protocol biopsy; rejection: acute; rejection: antibody-mediated (ABMR); rejection: chronic; translational research/science

Year:  2018        PMID: 30133953     DOI: 10.1111/ajt.15088

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  11 in total

Review 1.  Outstanding questions in transplantation: B cells, alloantibodies, and humoral rejection.

Authors:  Anita S Chong; David M Rothstein; Kassem Safa; Leonardo V Riella
Journal:  Am J Transplant       Date:  2019-04-10       Impact factor: 8.086

Review 2.  Non-canonical B cell functions in transplantation.

Authors:  Jeffrey L Platt; Marilia Cascalho
Journal:  Hum Immunol       Date:  2019-04-10       Impact factor: 2.850

3.  Notch3 expression in capillary pericytes predicts worse graft outcome in human renal grafts with antibody-mediated rejection.

Authors:  Yichun Xu-Dubois; Panagiotis Kavvadas; Zela Keuylian; Alexandre Hertig; Eric Rondeau; Christos Chatziantoniou
Journal:  J Cell Mol Med       Date:  2022-05-25       Impact factor: 5.295

4.  Poor Outcomes in Patients With Transplant Glomerulopathy Independent of Banff Categorization or Therapeutic Interventions.

Authors:  Kaiyin Wu; Danilo Schmidt; Covadonga López Del Moral; Bilgin Osmanodja; Nils Lachmann; Fabian Halleck; Mira Choi; Friederike Bachmann; Simon Ronicke; Wiebke Duettmann; Marcel Naik; Eva Schrezenmeier; Birgit Rudolph; Klemens Budde
Journal:  Front Med (Lausanne)       Date:  2022-05-12

Review 5.  The therapeutic challenge of late antibody-mediated kidney allograft rejection.

Authors:  Georg A Böhmig; Farsad Eskandary; Konstantin Doberer; Philip F Halloran
Journal:  Transpl Int       Date:  2019-05-07       Impact factor: 3.782

Review 6.  Therapies for Chronic Allograft Rejection.

Authors:  Min Young Kim; Daniel C Brennan
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

7.  Poor Long-Term Renal Allograft Survival in Patients with Chronic Antibody-Mediated Rejection, Irrespective of Treatment-A Single Center Retrospective Study.

Authors:  Kaiyin Wu; Danilo Schmidt; Covadonga López Del Moral; Bilgin Osmanodja; Nils Lachmann; Qiang Zhang; Fabian Halleck; Mira Choi; Friederike Bachmann; Simon Ronicke; Wiebke Duettmann; Marcel G Naik; Eva Schrezenmeier; Birgit Rudolph; Klemens Budde
Journal:  J Clin Med       Date:  2021-12-30       Impact factor: 4.241

8.  Data-Driven Kidney Transplant Phenotyping as a Histology-Independent Framework for Biomarker Discovery.

Authors:  Konrad Buscher; Barbara Heitplatz; Veerle van Marck; Jian Song; Sophie Loismann; Rebecca Rixen; Birte Hüchtmann; Sunil Kurian; Erik Ehinger; Dennis Wolf; Klaus Ley; Hermann Pavenstädt; Stefan Reuter
Journal:  J Am Soc Nephrol       Date:  2021-06-02       Impact factor: 14.978

Review 9.  The Role of Natural Killer Cells in the Immune Response in Kidney Transplantation.

Authors:  Paola Pontrelli; Federica Rascio; Giuseppe Castellano; Giuseppe Grandaliano; Loreto Gesualdo; Giovanni Stallone
Journal:  Front Immunol       Date:  2020-07-23       Impact factor: 7.561

10.  The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell- and antibody-mediated rejection.

Authors:  Alexandre Loupy; Mark Haas; Candice Roufosse; Maarten Naesens; Benjamin Adam; Marjan Afrouzian; Enver Akalin; Nada Alachkar; Serena Bagnasco; Jan U Becker; Lynn D Cornell; Marian C Clahsen-van Groningen; Anthony J Demetris; Duska Dragun; Jean-Paul Duong van Huyen; Alton B Farris; Agnes B Fogo; Ian W Gibson; Denis Glotz; Juliette Gueguen; Zeljko Kikic; Nicolas Kozakowski; Edward Kraus; Carmen Lefaucheur; Helen Liapis; Roslyn B Mannon; Robert A Montgomery; Brian J Nankivell; Volker Nickeleit; Peter Nickerson; Marion Rabant; Lorraine Racusen; Parmjeet Randhawa; Blaise Robin; Ivy A Rosales; Ruth Sapir-Pichhadze; Carrie A Schinstock; Daniel Seron; Harsharan K Singh; Rex N Smith; Mark D Stegall; Adriana Zeevi; Kim Solez; Robert B Colvin; Michael Mengel
Journal:  Am J Transplant       Date:  2020-05-28       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.